Kenvue
KVUE
$19.31
-1.28%
Kenvue is the world's largest pure-play consumer health company, spun out of Johnson & Johnson's consumer segment in May 2023, operating across three segments — Self Care (Tylenol, Nicorette, Listerine), Skin Health and Beauty (Neutrogena, Aveeno, Johnson's), and Essential Health — with over $15 billion in annual revenue and roughly 22,000 employees. Its portfolio of category-leading, household-name brands gives it a defensive, cash-generative profile typical of consumer staples, though it lacks the pricing power and scale advantages of larger diversified peers. The dominant investor narrative is no longer organic growth but the pending all-cash acquisition by Kimberly-Clark, announced in November 2025 and expected to close in the second half of 2026, which has effectively converted KVUE into a merger-arbitrage instrument whose price is anchored to deal terms rather than standalone fundamentals. Debate now centers on deal-completion risk — antitrust review, integration concerns, and litigation overhangs such as the Neutrogena product claims — alongside a modest underlying turnaround in earnings, with recent quarters showing YoY revenue growth and margin recovery that have kept shares bid near the top of their range.…
KVUE
Kenvue
$19.31
Related headlines
Investment Opinion: Should I buy KVUE Today?
Rating: Hold. The core thesis is that KVUE is no longer a standalone consumer-health investment but a merger-arbitrage instrument anchored to Kimberly-Clark's all-cash deal, with the $19.57 price sitting essentially at the $19.50 analyst average target (-0.4% implied) and a consensus Hold rating (mean 2.79 from 12 analysts). There is no fundamental upside left to capture; the return profile is a modest spread to deal value against binary completion risk.
Supporting evidence is mixed but leans defensive. Valuation is undemanding on a forward basis — forward PE of 15.79x versus trailing 22.32x, PEG of 0.524, EV/EBITDA of 13.77x and PS of 2.18x — while the 4.80% dividend yield is well above the 2.5%–3.0% staples norm and TTM FCF of $2.118 billion gives a roughly 6.4% FCF yield. Profitability is improving, with operating margin up from 16.71% in Q3 2025 to 17.88% in Q2 2026 and EPS up 9% YoY to $0.24. However, revenue growth of just 3.02% YoY and a 107.6% payout ratio cap the standalone case, and the $18.00–$23.00 target range shows the Street has no conviction beyond the deal.
The biggest risks that could invalidate the thesis are deal failure (antitrust delay or block), Neutrogena litigation escalation, and dividend sustainability given the 107.6% payout and 0.958 current ratio. This Hold would upgrade to Buy only on a revised, higher bid or a pullback toward the $17.20–$17.80 support zone that widens the spread to deal value; it would downgrade to Sell on credible signs of antitrust challenge or a break below $17.20. Verdict: fairly valued relative to the deal and its own history, with the forward multiple near the low end of its 15.8x–35.6x historical band — neither cheap nor expensive, simply priced for completion.
Sign up to view all
KVUE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.50 and implied upside of +1.0% versus the current price.
Average Target
$19.50
0 analysts
Implied Upside
+1.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
Twelve analysts cover KVUE with a consensus recommendation of Hold (mean rating 2.79 on a 1–5 scale), and an average target price of $19.50 — essentially at the current $19.57 price, implying roughly -0.4% downside and signaling that the Street views the stock as fairly valued pending deal completion. The consensus leans neutral rather than bullish, consistent with a merger-arbitrage setup in which the spread to deal value, not fundamental upside, drives returns; consensus EPS of $1.43 and revenue of $17.43 billion for the forward period reflect low-single-digit growth expectations.
The target range spans $18.00 to $23.00, a spread of about 28% of the current price that signals moderate uncertainty. The high target of $23.00 likely assumes a sweetened bid, successful integration, and multiple expansion toward premium staples peers, while the low target of $18.00 prices in deal risk — antitrust delay, litigation costs, or a re-rating toward standalone fair value. Institutional ratings show a uniformly cautious pattern: UBS, Barclays, Citigroup, and Canaccord have all maintained Neutral/Equal Weight/Hold stances through 2026 with no upgrades, reinforcing that conviction is low and the stock's near-term path depends on merger developments rather than analyst-driven catalysts.
Bulls vs Bears: KVUE Investment Factors
The evidence currently favors the bull side, but only narrowly and for the wrong reason: KVUE is not a growth story but a merger-arbitrage instrument, with the stock at $19.57 near its $20.13 high and the analyst average target of $19.50 implying essentially zero upside. The bull case rests on a 6.4% FCF yield, a 4.80% dividend, improving margins (operating margin up from 16.71% in Q3 2025 to 17.88% in Q2 2026) and 16.56 points of 1-year relative strength, while the bear case rests on a 107.6% payout ratio, sub-3% organic growth, a sub-1.0 current ratio and unanimous Hold ratings. The single most important tension is deal completion: if Kimberly-Clark closes in H2 2026 as expected, the stock is effectively a bond-like spread trade with capped upside; if antitrust review, Neutrogena litigation or integration concerns derail or delay the transaction, the shares would re-rate toward standalone fair value and the $18.00 low target becomes the relevant anchor. Momentum is real but the 3-month relative strength of -1.35 points shows the recent surge is a catch-up leg driven by deal headlines, not a fundamental re-rating.
Bullish
- Merger anchor caps downside: The pending all-cash Kimberly-Clark acquisition, announced November 2025 and expected to close in H2 2026, anchors KVUE's price to deal terms rather than standalone fundamentals. This is why the stock trades at $19.57, just 2.8% below its 52-week high of $20.13, and why beta is only 0.447 — the market is pricing completion, not organic growth.
- Momentum and relative strength: KVUE is up 29.69% over the past year versus 13.13% for SPY, a 16.56-point relative-strength advantage, and up 10.75% in the past month against a 1.02% SPY decline (11.77-point spread). The 12.99% YTD gain confirms durable accumulation rather than a single spike.
- Improving profitability and EPS: Q2 2026 net income of $456 million on a 17.88% operating margin compares with $330 million and 8.73% net margin in Q4 2025, while EPS rose to $0.24 from $0.22 a year ago (+9%). Interest expense fell to $90 million from $107 million, aiding the margin recovery.
- High FCF yield and dividend: TTM free cash flow of $2.118 billion against a roughly $33 billion market cap implies an FCF yield near 6.4%, comfortably funding the 4.80% dividend yield — well above the 2.5%–3.0% typical for consumer staples. Q2 2026 FCF of $826.8 million on $688 million operating cash flow shows healthy conversion.
Bearish
- Deal risk is the whole thesis: With the average analyst target of $19.50 essentially at the $19.57 price (-0.4% implied), there is virtually no fundamental upside left; returns depend entirely on deal completion. The $18.00 low target prices in antitrust delay or litigation costs, a 8% downside from current levels.
- Dividend exceeds earnings: The payout ratio of 107.6% means the 4.80% dividend is not covered by net income and relies on cash flow and balance-sheet flexibility. A current ratio of 0.958 (below 1.0) and debt-to-equity of 0.79 leave limited cushion if deal-related costs or litigation absorb cash.
- Sluggish organic growth: Q2 2026 revenue of $3.955 billion grew just 3.02% YoY, and the trailing four quarters totaled roughly $15.4 billion — low-single-digit growth typical of mature consumer health. Consensus forward revenue of $17.43 billion implies only modest acceleration, so standalone value creation is limited.
- Unanimously cautious Street: Twelve analysts rate KVUE a Hold (mean 2.79), and UBS, Barclays, Citigroup and Canaccord have all maintained Neutral/Equal Weight stances through 2026 with no upgrades. The $18.00–$23.00 target range (28% spread) signals uncertainty rather than conviction.
KVUE Technical Analysis
Kenvue is in a sustained uptrend, with the stock up 29.69% over the past year versus a 13.13% gain for SPY, a relative-strength advantage of 16.56 percentage points. At $19.57, the shares sit at roughly 90.5% of the 52-week range of $14.02–$20.13, just 2.8% below the high — a positioning that signals persistent accumulation and momentum but also leaves limited headroom before resistance and raises the risk of overextension, particularly with the stock having already re-rated toward deal-value levels. The 12.99% YTD gain confirms the trend has been durable rather than a single spike.
Short-term momentum is strongly positive and accelerating: the stock is up 10.75% over the past month against a 1.02% decline for SPY, a relative-strength spread of 11.77 points, and up 1.50% over three months. The one-month surge diverges sharply from the flattish three-month performance, reflecting a fresh catalyst-driven re-rating — most plausibly deal-closing optimism — rather than a broad trend reversal; the 6-month gain of 11.89% and 1-year gain of 29.69% show the longer-term trend remains intact. Notably, the 3-month relative strength of -1.35 points indicates KVUE lagged SPY over that window before the recent breakout, suggesting the current move is a catch-up leg that could extend or stall depending on merger headlines.
Key technical levels are well defined: support sits at the 52-week low of $14.02, with intermediate support near the September consolidation zone around $17.20–$17.80, while resistance is the 52-week high of $20.13 — a breakout above which would likely require confirmation of deal completion or a raised consideration. A breakdown below $17.20 would signal deal-risk repricing and open the door toward the mid-teens. Volatility is unusually low for an equity: beta of 0.447 means the stock moves roughly 45% as much as SPY, and a max drawdown of -23.06% over the period is modest, consistent with a defensive staples name trading on a merger anchor; this favors larger position sizing on a risk-adjusted basis but also means upside is capped by deal terms rather than market beta.
Beta
0.45
0.45x market volatility
Max Drawdown
-16.2%
Largest decline past year
52-Week Range
$14-$20
Price range past year
Annual Return
+35.6%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | +9.3% | -0.9% |
| 3m | +0.4% | +1.2% |
| 6m | +10.8% | +4.9% |
| 1y | +35.6% | +11.2% |
| ytd | +11.5% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Revenue is growing modestly but consistently: Q2 2026 revenue of $3.955 billion rose 3.02% YoY from $3.839 billion, following Q1 2026 revenue of $3.909 billion and Q4 2025 revenue of $3.780 billion, with the trailing four quarters totaling roughly $15.4 billion. Segment mix shows Self Care as the largest contributor at $1.589 billion, ahead of Essential Health at $1.253 billion and Skin Health and Beauty at $1.113 billion — a balanced portfolio where the beauty segment carries the highest margin potential but also the most competitive pressure. The low-single-digit growth trajectory is typical of mature consumer health and implies the investment case rests on margin execution and the merger rather than organic acceleration.
Profitability is solid and improving: Q2 2026 net income was $456 million on a 58.18% gross margin and 17.88% operating margin, with net margin of 9.72%, up from Q4 2025's $330 million and 8.73% net margin. Gross margin has been stable in the 56.5%–59.1% band over the past six quarters, while operating margin expanded from 16.71% in Q3 2025 to 17.67% in Q2 2026, aided by cost discipline and lower interest expense ($90 million versus $107 million a year earlier). EPS of $0.24 in Q2 2026 compares with $0.22 a year ago, a 9% improvement that supports the modest re-rating narrative.
Balance-sheet health is adequate but not fortress-like: debt-to-equity of 0.79 and a current ratio of 0.958 (below 1.0) indicate reliance on refinancing and working-capital management, though interest coverage of roughly 7.8x and ROE of 13.66% are respectable. Free cash flow TTM of $2.118 billion against a $32.95 billion market cap implies an FCF yield of about 6.4%, comfortably funding the 4.80% dividend yield — though the payout ratio of 107.6% means the dividend exceeds earnings and is covered by cash flow rather than net income. Q2 2026 operating cash flow of $688 million less $138.8 million capex produced $826.8 million of FCF, a healthy conversion that reduces dependence on external financing.
Quarterly Revenue
$4.0B
2026-06
Revenue YoY Growth
+3.0%
YoY Comparison
Gross Margin
58.2%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Because Kenvue is profitable — Q2 2026 net income of $456 million and trailing EPS of $0.0446 on a GAAP basis, with adjusted EPS far higher — the PE ratio is the appropriate primary metric. The trailing PE of 22.32x compares with a forward PE of 15.79x, a roughly 29% compression that implies the market expects meaningful earnings growth (consensus EPS of $1.43 versus the depressed trailing figure) and reflects the merger's influence on forward estimates. The PEG ratio of 0.524 suggests the stock is inexpensive relative to expected growth, though this metric is distorted by the deal context.
On a peer basis, KVUE trades at a PS of 2.18x and EV/EBITDA of 13.77x, with EV/Sales of 2.97x — multiples that sit at a discount to the premium end of consumer staples but roughly in line with large-cap household and personal products peers, many of which trade at 15x–20x EV/EBITDA. The 4.80% dividend yield is well above the sector's typical 2.5%–3.0%, a clear income premium that partly explains investor interest, while the 3.06x P/B is modest for a branded consumer franchise. The discount is arguably justified by sub-3% organic growth and the structural overhang of the pending acquisition, which caps multiple expansion.
Historically, KVUE's PE has ranged from roughly 17.2x (Q1 2026) to 35.6x (Q4 2024), and its PS ratio has fallen from 12.27x in Q1 2025 to 2.18x today — a dramatic de-rating driven by earnings normalization and the merger anchor. At 22.3x trailing PE, the stock sits in the lower-middle of its own historical band, while the forward multiple of 15.8x is near the low end, suggesting the market is pricing deal completion rather than standalone optimism; if the transaction closes, the relevant benchmark becomes the deal consideration, making further multiple expansion unlikely absent a revised bid.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a balance sheet that is adequate but not fortress-like. Debt-to-equity of 0.79 and a current ratio of 0.958 (below 1.0) mean the company relies on refinancing and working-capital management, while the 107.6% payout ratio means the 4.80% dividend exceeds net income and is covered only by cash flow. Interest coverage of roughly 7.8x and ROE of 13.66% are respectable, but Q2 2026 net income of $456 million on $3.955 billion revenue (9.72% net margin) leaves little room for a litigation charge or integration cost without pressuring the payout. Revenue concentration in mature categories — Self Care at $1.589 billion, Essential Health at $1.253 billion and Skin Health and Beauty at $1.113 billion — with only 3.02% YoY growth means there is no organic buffer if costs rise.
Market and competitive risks are dominated by the merger. Because the stock trades at $19.57, just 2.8% below its $20.13 high and roughly 90.5% of its 52-week range, there is limited headroom and the risk of overextension is real; a breakdown below the $17.20–$17.80 September consolidation zone would signal deal-risk repricing. Valuation compression is a secondary risk: trailing PE of 22.32x sits in the lower-middle of its historical 17.2x–35.6x band, and the PS ratio has collapsed from 12.27x in Q1 2025 to 2.18x today, so further multiple expansion is unlikely absent a revised bid. Beta of 0.447 means macro sensitivity is low, but that also means the stock will not be rescued by a broad market rally; recent news explicitly warns of integration risks and near-term volatility as the Kimberly-Clark deal nears closing, and Neutrogena product litigation remains an unresolved overhang.
In a worst-case scenario, antitrust review delays or blocks the Kimberly-Clark transaction while Neutrogena litigation costs escalate, forcing the market to value KVUE on standalone fundamentals of sub-3% growth and a stretched dividend. The stock would then retrace toward its 52-week low of $14.02 — a decline of roughly 28% from $19.57 — and the analyst low target of $18.00 (-8%) would likely prove too optimistic. The historical max drawdown of -23.06% provides a comparable magnitude, implying an investor could lose 23%–28% in this adverse scenario, with the dividend itself at risk given the 107.6% payout ratio.
FAQ
The most severe risk is deal failure: if antitrust review delays or blocks the Kimberly-Clark acquisition, the stock could fall toward the $18.00 analyst low target or the $14.02 52-week low, a decline of up to 28%. Second is litigation, particularly Neutrogena product claims, which could trigger charges against a 9.72% net margin. Third is dividend sustainability, since the 107.6% payout ratio exceeds earnings and a 0.958 current ratio leaves little cushion. Fourth is growth stagnation — revenue rose only 3.02% YoY in Q2 2026 — which limits standalone re-rating potential and leaves the stock dependent on merger headlines rather than fundamentals.
The 12-month forecast is dominated by the pending Kimberly-Clark acquisition. The base case (55% probability) targets $18.50–$20.13 as the deal closes in H2 2026 and the stock trades near deal consideration, anchored by the $19.50 analyst average target. The bull case (20%) targets $21.50–$23.00 on a sweetened bid or clean regulatory clearance with multiple expansion toward peer EV/EBITDA levels, while the bear case (25%) targets $14.02–$18.00 if antitrust or litigation derails the transaction. The most likely outcome is the base case, whose key assumption is on-schedule completion without material regulatory delay.
KVUE looks fairly valued to modestly cheap on forward metrics but not on trailing ones. The trailing PE of 22.32x sits in the lower-middle of its historical 17.2x–35.6x band, while the forward PE of 15.79x is near the low end and implies roughly 29% earnings growth to consensus EPS of $1.43. EV/EBITDA of 13.77x and PS of 2.18x are in line with large-cap household products peers, many of which trade at 15x–20x EV/EBITDA, and the PS ratio has collapsed from 12.27x in Q1 2025. The market is paying a fair price that embeds deal completion rather than standalone optimism, so further multiple expansion is unlikely absent a revised bid.
From a risk/reward perspective, KVUE offers limited upside and meaningful binary risk. At $19.57 it trades essentially at the $19.50 analyst average target (-0.4% implied) with a consensus Hold rating of 2.79 from 12 analysts, so the fundamental upside is largely exhausted. The bull case rests on a 4.80% dividend yield, a roughly 6.4% FCF yield on $2.118 billion TTM free cash flow, and a forward PE of 15.79x, while the biggest downside is deal failure, which could take shares toward the $18.00 low target or the $14.02 52-week low (-28%). It is a reasonable buy for income and merger-arbitrage investors comfortable with completion risk, but not for growth-oriented buyers.
KVUE is better suited to a defined event-driven horizon than a long-term growth holding. Its beta of 0.447 and max drawdown of -23.06% indicate low volatility, and the 4.80% dividend yield rewards patience, but the pending all-cash acquisition expected to close in H2 2026 means the investment case has a finite timeline tied to deal completion. Earnings visibility is moderate — operating margin improved from 16.71% in Q3 2025 to 17.88% in Q2 2026 — but revenue growth of just 3.02% YoY limits long-term compounding. A suggested minimum holding period is 6–12 months, spanning the expected closing, with position sizing appropriate for binary event risk.